Keryx Biopharmaceuticals (NASDAQ:KERX) and Ascendis Pharma A/S (NASDAQ:ASND) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, risk, earnings, dividends, analyst recommendations, institutional ownership and valuation.
This table compares Keryx Biopharmaceuticals and Ascendis Pharma A/S’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Ascendis Pharma A/S||-1,275.08%||-40.86%||-37.23%|
This table compares Keryx Biopharmaceuticals and Ascendis Pharma A/S’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Keryx Biopharmaceuticals||$60.64 million||0.00||-$163.44 million||($0.88)||N/A|
|Ascendis Pharma A/S||$12.50 million||380.25||-$153.65 million||($3.74)||-30.24|
Ascendis Pharma A/S has lower revenue, but higher earnings than Keryx Biopharmaceuticals. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than Keryx Biopharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Keryx Biopharmaceuticals has a beta of 2.35, suggesting that its stock price is 135% more volatile than the S&P 500. Comparatively, Ascendis Pharma A/S has a beta of 1.01, suggesting that its stock price is 1% more volatile than the S&P 500.
Institutional & Insider Ownership
69.0% of Keryx Biopharmaceuticals shares are held by institutional investors. Comparatively, 95.5% of Ascendis Pharma A/S shares are held by institutional investors. 1.6% of Keryx Biopharmaceuticals shares are held by company insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
This is a breakdown of recent ratings and target prices for Keryx Biopharmaceuticals and Ascendis Pharma A/S, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Ascendis Pharma A/S||0||0||9||0||3.00|
Keryx Biopharmaceuticals presently has a consensus price target of $6.75, suggesting a potential upside of ∞. Ascendis Pharma A/S has a consensus price target of $135.00, suggesting a potential upside of 19.38%. Given Keryx Biopharmaceuticals’ higher possible upside, research analysts plainly believe Keryx Biopharmaceuticals is more favorable than Ascendis Pharma A/S.
Keryx Biopharmaceuticals beats Ascendis Pharma A/S on 7 of the 13 factors compared between the two stocks.
Keryx Biopharmaceuticals Company Profile
Keryx Biopharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on providing medicines for patients with kidney disease in the United States. It markets its lead product Auryxia (ferric citrate), an orally available, absorbable, iron-based medicine for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis, as well as for the treatment of iron deficiency anemia in adults with CKD not on dialysis. The company has strategic alliances with Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. for the development and commercialization of ferric citrate in Japan; and with Panion & BF Biotech, Inc. for the development and marketing of ferric citrate. Keryx Biopharmaceuticals, Inc. was founded in 1997 and is headquartered in Boston, Massachusetts.
Ascendis Pharma A/S Company Profile
Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone that is in Phase I clinical study for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia. It also has strategic collaborations with Sanofi to develop TransCon Peptides for the treatment of diabetes; and Genentech and Roche to develop TransCon anti-vascular endothelial growth factor (VEGF), a compound to support injection of anti-VEGF in ophthalmology. Ascendis Pharma A/S was founded in 2006 and is headquartered in Hellerup, Denmark.
Receive News & Ratings for Keryx Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.